Evidence that cytotoxic T cells are part of the host's response to influenza pneumonia.

Cytotoxic T cells were detected in the cervical lymph nodes, lungs, spleen, and peripheral blood of mice with influenza. Lymphocytes decreased in the peripheral circulation and increased in the lung during the period of acute inflammation and pneumonia. Peak cytotoxic T-cell activity was present at the time of marked pulmonary infiltration, and it decreased with resolution of the pneumonia. The cytotoxic T cells in the lung were shown to be H-2 restricted and specific for the hemagglutinin of the infecting virus. The results indicate that hemagglutinin specific cytotoxic T cells are (a) induced during influenza infection; (b) they circulate in the blood; (c) they are present in greatest number; and (d) they have their peak cytotoxic effect when pneumonia is most marked. We interpret the results to indicate that specific cytotoxic T cells in the infected target organ are part of the immunological and pathological response to virus infection.

Development of a new in vivo anaphylactic histamine release assay in rats.

A new method has been developed to detect antigen-induced histamine release in the blood of allergic rats. This in vivo model of systemic anaphylaxis has been utilized to evaluate drugs for histamine release inhibition activity. Compounds were administered by various routes at appropriate times prior to or concomitant with antigen challenge. One minute after challenge the rats were bled into tubes containing heparin and aminoguanidine. Histamine concentrations were determined by a radioenzyme technique after separation of the plasma. Experiments demonstrated that: (a) rats passively sensitized with reaginic serum exhibited elevated blood histamine upon i.v. antigen challenge in a reproducible and dose-dependent manner; (b) heat-treatment of the reaginic serum abolishes antigen-induced histamine release; and (c) antigen-induced histamine release is inhibited by disodium cromoglycate, in a dose-dependent manner and it is also inhibited by isoproterenol or isobutyl-methylxanthine.

Autogenous vaccine treatment of juvenile laryngeal papillomatosis.

Seventeen cases of juvenile laryngeal papillomatosis have been seen and treated with microlaryngoscopy, removal of papillomas, and administering of autogenous vaccine. Holinger's original findings could be confirmed. The operation frequency of 9 patients was significantly reduced, 5 were improved, and 3 unchanged. In no case was an undesirable reaction to the vaccine observed. Electron microscopy showed no virus-like particles in the papilloma but a section of a vulvar wart did show the virus.

Regional T- and B-cell responses in influenza-infected ferrets.

Ferrets were infected with A/Port Chalmers/72 influenza virus and the T- and B-cell responses in the spleen, in lymph nodes draining the upper and lower respiratory tract, and in lung washings were examined in vitro. Lymphocyte responses were measured by using a hemolytic plaque assay for B cells and a proliferation assay for T cells. Virus and antibody levels were measured in respiratory tract washings, and antibody titers were measured in sera from infected animals. Individual B cells secreting specific antibody to A/Port Chalmers/72 virus were detected in regional lymph node and spleen preparations as early as 3 days and as late as 43 days after infection. T-cell assays showed an in vitro response of lymph node cells to A/Port Chalmers/73 virus from day 6 to day 43. Virus was isolated from the respiratory tract up to 7 days after infection. Serum hemagglutination-inhibiting antibody was first detectable on day 6, with maximum titers reached by day 10. These results demonstrated that antibody production and a cellular immune responses were detectable at regional sites at a time when virus was still present and before serum antibody was measured.

Mercaptan-induced fragmentation of a subunit-like proteolytic fragment of immunoglobulin M.

Limited papain hydrolysis of immunoglobulin M (IgM) produces a subunit-like proteolytic fragment designated IgM(p) (Inman & Hazen, 1968). In the presence of mercaptans, IgM(p) partially dissociated into Fc(mu)-like and Fab(mu) fragments. Treatment of residual IgM (that remaining after a papain digestion) with 2mm-mercaptoethylamine resulted in fragmentation of the same type that occurs in a routine limited digestion of IgM with papain, although exogenous enzyme was not added to the mixture. When IgM was hydrolysed with (14)C-labelled papain, a small quantity of the enzyme was found to be associated with the residual IgM and IgM(p) fractions. IgM and IgM 7S subunit (IgM(s)) that had been exposed to papain in the absence of activating mercaptan and separated from the enzyme by gel filtration also fragmented when subsequently treated with 2mm-mercaptoethylamine. The fragments resembled those produced during a typical limited papain digestion of IgM. It was concluded that mercaptoethylamine induced fragmentation of IgM(p) by activating adsorbed papain.

Regulation of in vivo IgE biosynthesis in mice with complete Freund's adjuvant.

Complete Freund's adjuvant (CFA) administered before sensitization dampened the normal and cyclophosphamide-enhanced response of high and moderate IgE responder phenotype mice (CAF1 and C57B1/6J, respectively). CFA-induced suppression of IgE biosynthesis was effective in reducing anaphylactic histamine release from approximately 2,900 ng histamine per milliliter to background levels (less than 100 ng/ml). CFA-induced ascites fluid was able to reduce the cyclophosphamide-enhanced IgE response of low-responder phenotype SJL mice from 1:320 to less than 1:5 as determined by passive cutaneous anaphylaxis. Muramyl dipeptide, a mycobacterial cell wall component capable of eliciting effects similar to those seen with CFA, was shown to induce suppression of IgE production if incorporated in incomplete Freund's adjuvant. Muramyl dipeptide administered in saline was ineffective, while incomplete Freund's adjuvant alone had some immunoregulatory properties. Ongoing IgE responses were less susceptible to regulation. CFA administered to sensitized C57B1/6J mice was ineffective in inducing IgE suppression when animals were challenged with antigen.

Histology of and quantitative assays for oxazolone-induced allergic contact dermatitis in mice.

Oxazolone-induced allergic contact dermatitis in mice has been used as an in vivo model for identifying potential anti-inflammatory and immune-modulating drugs. Studies were conducted with this model to detail the histokinetics of the inflammatory response and to examine the adequacy of three assays for measuring the intensity of the inflammatory response when compared to histologic findings. CD-1 mice were sensitized with oxazolone on the flank and challenged on the dorsum of the ear pinna. The inflammatory response was quantitated by measuring the change in pinna weight and thickness and presence of 125I-2-deoxyuridine (125IUDR)-labeled cells. Cellular infiltrate was mixed with general predominance of mononuclear cells over neutrophils. Correlation with the histologic data suggests that both the ear weight and thickness assays are suitable primary screening assays, since both provided a sensitive, accurate and objective measure of the inflammatory response and its suppression by dexamethasone. The 125IUDR assay worked well in untreated mice but was unsatisfactory in mice treated topically or systemically with dexamethasone.

Inhibition of anaphylactic histamine release and pulmonary distress in rats by nonspecific IgE.

Myeloma IgE, obtained from ascitic fluid of rats previously inoculated with the IgE-producing cell line IR-162, was administered in prophylactic and therapeutic regimens to rats passively and actively sensitized to ovalbumin. Administration of myeloma IgE prior to passive sensitization resulted in approximately 95% inhibition of anaphylactic histamine release and significant protection from anaphylactic pulmonary distress. Myeloma IgE treatment prior and subsequent to active sensitization brought about a 70-80% inhibition of anaphylactic histamine release. A similar pattern of protection was seen in animals that received 5 but not 3 weekly myeloma IgE treatments subsequent to active sensitization. These findings indicate that treatment with nonspecific IgE prior to sensitization is effective in blocking anaphylactic reactions but competition with cell-bound IgE in sensitized animals requires prolonged administration of relatively large quantities of 'nonsense' IgE.

Induction of hamster T cell-specific antiserum in rabbits using hamster brain tissue.

Antiserum specific for hamster thymus-derived lymphocytes, prepared by immunizing rabbits with hamster brain tissue, was cytotoxic to hamster thymocytes greater than lymph node cells greater than spleen cells, while virtually non-reactive against bone marrow. This antiserum inhibited spleen cell response to the T cell mitogen, phytohemagglutinin, but not to lipopolysaccharide, a B cell mitogen.

Effect of misoprostol on histamine-stimulated acid secretion and cyclic AMP formation in isolated canine parietal cells.

Isolated canine parietal cells were used to study the ability of misoprostol to inhibit acid secretion in the presence of a number of acid secretagogues. Misoprostol inhibited histamine-stimulated acid secretion in a dose-dependent and noncompetitive manner. A concentration of 2-3 X 10(-9) M misoprostol inhibited maximal histamine-stimulated acid secretion by one half. Misoprostol had little to no effect on acid secretion stimulated by carbachol and dibutyryl cAMP, had no effect on the acid secretion directly stimulated by pentagastrin, and only modestly inhibited acid secretion stimulated by forskolin. Misoprostol noncompetitively inhibited cAMP formation in response to histamine, with an IC50 value similar to that for the inhibition of histamine-stimulated acid secretion. These results indicate that: (1) misoprostol specifically inhibits histamine-stimulated acid secretion in parietal cells, and (2) the antisecretory action of misoprostol is closely related to the reduction of histamine-stimulated cAMP formation with the site of major action most likely in the coupling process between histamine H2 receptor sites and histamine-sensitive adenylate cyclase.

Specificity studies on cytotoxic thymus-derived lymphocytes reactive with influenza virus-infected cells: evidence for dual recognition of H-2 and viral hemagglutinin antigens.

Cytotoxic thymus-derived (T) lymphocytes were readily detected in spleens of mice inoculated intranasally with mouse-adapted A/Port Chalmers (H3N2), A/England (H3N2), A/PR/8 (H0n1), and B/Hong Kong influenza viruses. T-cell-mediated lysis of H-2 compatible target cells infected with the strain of virus used to immunize the mice was considerably higher than lysis of either syngeneic cells infected with a different strain of influenza virus or allogeneic cells infected with the immunizing strain of influenza virus. The findings that cytotoxic lymphocytes can distinguish minor antigenic variants among influenza viruses and that lysis depends on H-2 histocompatibility between lymphocyte and target cell support the concept of dual recognition of visual and H-2 histocompatibility antigens in T-cell-mediated antiviral immunity.

Mitogenicity of influenza hemagglutinin glycoproteins and influenza viruses bearing H2-hemagglutinin.

The hemagglutinin glycoprotein is responsible for the mitogenic effect of influenza A viruses of the H2N2 subtype. This was indicated by the ability of viruses bearing the H2-hemagglutinin glycoprotein, regardless of its associated neuraminidase, to induce lymphocyte proliferation in normal spleen cell suspensions and by the ability of antisera with specificity for the H2-hemagglutinin to block this response. Moreover, purified hemagglutinin from representative viruses from the H0N1, H1N1, H2N2, H3N2, and influenza B subtypes were also shown to be mitogenic.

Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine.

Recently defined aspects of cellular and humoral antiviral immunity were evaluated in 10 young adults given influenza vaccines containing A/USSR/77 (H1N1) antigens. Cytotoxic lymphocytes were measured by using cryopreserved lymphocytes as effector cells and syngeneic, virus-infected lymphocytes as target cells. An assay previously developed in this laboratory was adapted for the measurement of antibody-dependent, complement-mediated cytotoxicity. Antiviral cytotoxic lymphocyte responses were detected in 5 of 10 volunteers between 3 and 10 days after the initial vaccination. These responses were found both in individuals who were previously primed and in individuals who were not primed to influenza A/USSR/77 antigens. The complement-mediated lysis assay was found to be more sensitive than the hemagglutination inhibition test and probably detected antibodies to both subtype-specific and cross-reactive antigenic determinants. These responses to influenza antigens are similar to those obtained in studies of murine influenza which indicate that cytotoxic lymphocytes and antibody-dependent, complement-mediated cytotoxicity have a role in the early response to acute infection.

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.

BACKGROUND: Many patients with non-Hodgkin's lymphomas are not cured by current therapies, and new approaches to treatment are needed. As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. METHODS AND RESULTS: Anti-B1 (anti-CD20) mouse monoclonal antibody trace-labeled with 131I (15 mg containing 5 mCi) was given intravenously at approximately one-week intervals: first, without pretreatment with unlabeled anti-B1 antibody, to all 10 patients; then, with pretreatment with 135 mg of unlabeled antibody, to 8 patients; and then, with pretreatment with 685 mg, to 2 patients. Serial quantitative gamma-camera images and measures of whole-body radioactivity were obtained after each tracer dose. All known disease sites larger than 2 cm could be imaged. The effect of a pretreatment dose of unlabeled anti-B1 antibody on targeting of the tumor with the radiolabeled antibody was variable. The pretreatment dose of unlabeled antibody that produced the highest ratio of the tumor dose to the whole-body dose in tracer studies was then used to deliver higher doses of radioactivity for radioimmunotherapy in nine patients. Three patients received doses designed to deliver 25 cGy to the whole body (two patients treated twice, six to eight weeks apart), four patients received 35 cGy (one patient treated twice), and two patients received 45 cGy (one patient treated twice); each dose contained 34 to 66 mCi of activity. Six of the nine treated patients had tumor responses, including patients with bulky or chemotherapy-resistant disease: four patients had complete remissions, and two had partial responses. Three patients had objective responses to tracer infusions before they received radioimmunotherapeutic doses. Of the four patients with complete remissions, one remained in remission for eight months and the other three continue to have no disease progression (for 11, 9, and 8 months). There was mild or no myelosuppression. CONCLUSIONS: Radioimmunotherapy with [131I]anti-B1 antibody is a promising new treatment for lymphoma.